Home > Keywords > Thématique > Science

Science

Articles

  • How blood–brain barrier technology is unleashing CNS therapies
    18 March, by Emmanuelle BETTENDORF

    We are proud to be featured in Nature, in an article exploring how we are enabling targeted drug delivery across the blood–brain barrier.
    This article highlights the potential of our VECTrans platform, which has the potential to transform the treatment of neurodegenerative disorders. The article goes into the science and data behind our approach as well as our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.
    Click below for the full article.
    👉 (…)

  • mRNA Based Therapeutics poster
    3 February, by Emmanuelle BETTENDORF

    Pavlo Shpak-Kraievskyi is presenting a poster on behalf of Vect-Horus at the 4th Annual mRNA-Based Therapeutics Summit Europe, taking place January 28-30 in Frankfurt, Germany.
    Effective delivery of mRNA therapeutics to the central nervous system (CNS) remains a significant challenge due to the protective blood-brain barrier (BBB). The poster, entitled “VECTrans® Technology for CNS Targeting with Lipid Nanoparticles”, outlines results from a study of VECTrans® enabling the targeted (…)

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

  • Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
    22 April 2024, by Emmanuelle BETTENDORF

    Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the publication of a paper in the open-access scientific journal Pharmaceutics Vol 26 (MDPI).
    The paper, entitled “LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo”, outlines a study which showed how peptides (…)

  • Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
    3 April 2023, by Elodie DORMES

    Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
    Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

  • Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
    28 January 2019, by Jonathan NOWAK

    Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
    Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

  • Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
    15 May 2024, by Emmanuelle BETTENDORF

    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.
    The study showed that these vectors have the potential to improve delivery of medication to the (…)

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
    15 November 2022, by Elodie DORMES

    Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) — RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC). This radiotracer will serve as a companion diagnostic for future Targeted Alpha Therapy (TAT) for these cancers. 68Ga-RMX-VH is a (…)

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f